What BiomimX does

BiomimX S.r.l. (founded 2017, Milan, Italy) is a privately held biotech spin-off of Politecnico di Milano that develops beating Organs-on-Chip platforms used as preclinical drug-screening tools. Its patented uBeat® technology delivers controlled mechanical stimulation to 3D microtissues through the uBoX Pro hardware device, replicating native human microenvironments such as heartbeat, peristalsis and mechanical loading without chemical induction. The current product portfolio comprises the uHeart (Heart-on-a-Chip with real-time electrophysiology), uKnee (Cartilage-on-Chip, healthy and osteoarthritic), uGut (gastrointestinal tract with peristalsis and microbiome capability), uScar (cardiac fibrosis), uHep (liver sinusoid), and the multi-organ LivHeart (heart + liver) model, with uLung and uBite in development.

BiomimX monetizes through two streams: (i) hardware product sales of the uBeat® Platform and uBoX Pro to laboratories that wish to run their own organ-on-chip experiments (e.g., Queen Mary University of London as a confirmed equipment customer), and (ii) contract research services using the company's validated human in vitro models for cardiotoxicity screening, drug efficacy studies, and IND-enabling work (used, for example, in Synartro's SYN321 IND submission). Pricing is custom and not publicly disclosed; both products and services are sold via a direct enterprise field-sales motion targeting pharmaceutical, biotech, medical-device, academic and CRO customers across EMEA, North America and Scandinavia.

The company is co-founded and led by CEO Paola Occhetta and President Marco Rasponi (Politecnico di Milano professors), with Roberta Visone as COO. It has been funded almost entirely through non-dilutive sources — Italian government grants (Invitalia Smart&Start, Brevetti+, Regione Lombardia), competition prizes (StartCup Lombardia, Cross the Bridge, TERMIS), H2020 and Horizon Europe consortium participation (SINERGIA, PHOENIX, MIRACLE, IMPLANTEU), and the Berkeley SkyDeck Europe Milan accelerator — with no venture or growth-equity rounds disclosed. In February 2026 BiomimX became a founding member of IAMPS (Industry Alliance for Microphysiological Systems), with its CEO serving as Vice-President for Regulatory Adoption & Partnerships. The company employs 1-10 people and reports no public revenue figure.

Name

BiomimX

Legal name

BiomimX S.r.l.

Website

http://www.biomimx.com/

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

BiomimX S.r.l. is an Italian biotech spin-off of Politecnico di Milano that develops patented uBeat® beating Organs-on-Chip (uHeart, uKnee, uGut, uScar, uHep, LivHeart) and sells hardware plus contract research services to pharmaceutical, biotech, medical-device, CRO and academic customers for drug-safety and efficacy screening.

Ownership category

akta.pro rank

Product category

Organ-on-Chip Platforms

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)

akta.pro secondary industries

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)

Keywords

• Organ-on-chip platforms
• Drug safety screening
• In vitro disease models
• Microphysiological systems
• Preclinical drug testing

Headquarters

HQ city

Bresso

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Product Sales - uBeat® Platform & uBoX Pro: Sale of hardware platforms and equipment for organ-on-chip research, including the uBeat® Setup supporting culture of 3D microtissue models and the uBoX Pro mechanical stimulation device
2. Contract Research Services: Fee-for-service testing using company's human in vitro models for drug safety toxicology and efficacy assessment. Services include cardiotoxicity screening, drug efficacy studies, and custom assay development for pharmaceutical and biotech clients

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

BiomimX develops and sells the patented uBeat® organ-on-chip platform with the uBoX Pro mechanical stimulation hardware device, enabling the creation of dynamic 3D human microtissue models (heart, cartilage, gut, fibrosis, liver). The company sells this hardware directly to pharmaceutical, biotech, and academic customers, and additionally provides fee-for-service contract research using its validated human in vitro models for drug safety toxicology, cardiotoxicity screening, and efficacy testing.

Product overview

BiomimX is a life sciences company offering the uBeat® Platform as its core technology, which provides mechanical stimulation to generate 3D human microtissue models. The product portfolio centers on this patented platform and includes multiple organ-on-chip models: uHeart (cardiac), uKnee (cartilage/OA), uGut (gastrointestinal), uScar (cardiac fibrosis), uHep (liver), LivHeart (multi-organ heart+liver), uLung, and uBite (both in development). The uBoX Pro is the mechanical stimulation hardware device. The company also provides contract research services using these models for drug discovery, safety-toxicology assessment, and efficacy testing, serving pharmaceutical and biotech companies seeking human-relevant preclinical alternatives to animal testing.

Differentiator

Problem solved

Functional benefit

Brands

• uBeat®: Patented technology platform providing controlled mechanical stimulation to 3D microtissues, mimicking native human tissues. Powers the company's organ-on-chip product line including uHeart, uKnee, uGut, uScar models.

Products and services

• uBeat® Platform & uBoX Pro

Quantifiable outcome

• 83.3% sensitivity, 100% specificity, 91.6% accuracy in detecting drug-induced cardiotoxicity
• +3 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

17 partnerships are on record, tiered core, major and minor.

• IAMPS (Industry Alliance for Microphysiological Systems)coreStrategic or Co-development Partner · 10 February 2026Founding member of IAMPS, the world's first industry association dedicated to Microphysiological Systems. CEO Paola Occhetta serves as Vice-President for Regulatory Adoption & Partnerships. Association aims to increase regulatory acceptance of MPS data, create data-sharing platforms, and advance device standardization.
• Politecnico di MilanocoreStrategic or Co-development PartnerAcademic spin-off originating from Politecnico di Milano. Ongoing collaboration through MiMic Lab for technology development and R&D projects including SINERGIA, PHOENIX. Co-founder Marco Rasponi is Professor at Politecnico di Milano.
• Accelera SrlcoreStrategic or Co-development PartnerNon-exclusive commercial agreement following scientific collaboration for drug discovery. Collaboration validated uHeart model with 12 reference compounds for cardiotoxicity detection. Accelera is part of NMS Group.
• Fidia FarmaceuticimajorStrategic or Co-development PartnerResearch collaboration agreement signed September 2021 for applying Organs-on-Chip solutions to intra-articular medical device discovery process, including uKnee model validation with anti-inflammatory drugs.
• Istituto Europeo di Oncologia (IEO)majorStrategic or Co-development PartnerCollaboration on gut-on-chip model incorporating human fecal samples. uGut publication in Nature Biomedical Engineering February 2025 demonstrating microbiome-immune checkpoint inhibitor interaction predictions.
• University of BaselmajorStrategic or Co-development PartnerScientific partner for knee-on-chip and joint-on-chip development. SNSF/Innosuisse BRIDGE PoC grant collaboration for osteoarthritis model development.
• Politecnico di TorinomajorStrategic or Co-development PartnerCollaboration on cardiac fibrosis model (uScar) and gene therapy testing. Tested innovative gene therapy for cardiac reprogramming in uScar model.
• Queen Mary University of LondonminorOthersAcquired BiomimX uBeat® setup for educational and research facilities. Funded through NC3Rs and BBSRC large infrastructure grant plus commercial partnerships and research grants.
• Humanitas HospitalminorStrategic or Co-development PartnerCollaboration on genetic cardiomyopathy modeling within PHOENIX EU project framework.
• SynartromajorChannel Partner/ Reseller/ DistributorSwedish biotech company developing anti-OA combined injectable therapy (SYN321). BiomimX provided efficacy data from uKnee model used in IND application for clinical trials.
• NeuroZone SrlminorChannel Partner/ Reseller/ DistributorStrategic commercial partnership for uKnee services signed May 2020.
• ChiesiminorOthersPharmaceutical company client for organ-on-chip testing services.
• UCBminorOthersPharmaceutical company client for organ-on-chip testing services.
• HaleonminorOthersConsumer health company client for organ-on-chip testing services.
• Charité BerlinminorOthersHealthcare institution client for organ-on-chip services.
• MIRACLE ConsortiummajorStrategic or Co-development PartnerEU-funded Horizon Europe MSCA project (Grant 101119370) focusing on inflammatory regulation in cardiometabolic disease. 13 partner institutions including academic, SMEs, and pharmaceutical companies (AstraZeneca).
• PHOENIX ConsortiummajorStrategic or Co-development PartnerEU-funded Horizon Europe project (Grant 101156638) coordinated by Politecnico di Milano. Develops next-generation OoC platforms for cardiac and neuro-muscular disease modeling. 9 partners over 4 years.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Emulate: US-based organ-on-chip pioneer commercializing the Chip-A1 platform across liver, lung, intestine and other tissues. Most direct competitor in MPS-based preclinical testing serving the same pharma/biotech buyer base.
• MIMETAS: Dutch organ-on-chip company offering the OrganoPlate platform for high-throughput 3D tissue models. Overlapping pharma services model and complementary tissue portfolio, led by a founding executive also in IAMPS leadership.
• TissUse: German multi-organ-chip developer (MOC) with a HUMIMIC platform used for substance testing and ADME applications. Comparable multi-organ positioning and EU regulatory engagement, with overlap in pharma services revenue.
• CN Bio Innovations: UK-based organ-on-chip company with PhysioMimix liver and lung MPS used in drug discovery and toxicology. Direct competitor in MPS-based contract research for pharmaceutical customers.
• NETRI: French organ-on-chip firm offering microfluidic neural and other organ models for industrial applications. Competes in the same MPS vendor landscape and is a fellow IAMPS founding member, with overlapping EU regulatory advocacy.
• InSphero: Swiss 3D in vitro model provider specializing in organoids and microtissues for safety and efficacy testing. Closely comparable in 3D microtissue model offerings (liver, islet, others) and direct CRO-service revenue model.
• React4Life: Italian organ-on-chip company offering the MIVO platform for in vitro testing. Same home-country peer, comparable product/service proposition, and previously co-hosted Italian OoC industry workshops with BiomimX.
• IVTech Srl: Italian start-up developing fluidic and MPS platforms for organ-on-chip research. Direct domestic peer with overlapping EU funding base and co-organized the 2022 Italian Organ-on-Chip industry workshop with BiomimX.
• Kirkstall: UK-based organ-on-chip and microfluidics company offering the Quasi Vivo multi-chamber system for connected tissue culture. Overlaps with BiomimX in pharma toxicology research and the same regulatory acceptance narrative.

Broad incumbents

• Charles River Laboratories: Large global CRO with a growing portfolio of MPS and organ-on-chip services (e.g., Endosafe, Early Discovery). Represents the incumbent channel threat that could absorb MPS testing demand if BiomimX does not secure regulatory moat.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/BiomimX
• YouTubeyoutube.com/channel/UC14N4yYd2ig1PoIuae55JJA
• Facebookit-it.facebook.com/pg/biomimx/about
• LinkedInit.linkedin.com/company/biomimx

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BiomimX